PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

A COVID-19 vaccine in early November? ‘Extremely unlikely, but not impossible’: Warp Speed head Slaoui

With COVID-19 vaccine hype intensifying each day—including this week, with new comments from Pfizer’s CEO—the head of the U.S. government’s research program said it’s “extremely unlikely” a vaccine will be available in early November.

Moncef Slaoui, the Operation Warp Speed head, told NPR it remains “extremely unlikely, but not impossible” a vaccine will be ready by early November. Operation Warp Speed, a multibillion-dollar research program aimed at delivering 300 million doses of a COVID-19 vaccine by January, is performing “even better than I was hoping,” he said. With that, “there is a very, very low chance that the trials that are running as we speak could read before the end of October” and help score an emergency use authorization or approval.

Slaoui’s comments diverge from those of Pfizer CEO Albert Bourla, who this week said his company expects enough data in late October to make a decision about an FDA submission. In fact, the drug giant is already preparing its submission in case the vaccine shows early efficacy in the trial, Bourla said.

Meanwhile, the Centers for Disease Control and Prevention is working with states and localities to prepare vaccine distribution sites for Nov. 1, according to press reports from earlier this week. Pfizer, Moderna and AstraZeneca vaccines are already in late-stage testing, but it’s unclear when the studies will produce sufficient safety and efficacy data. It’s also unclear how long it would take to get data published and how long an FDA review would take.

That Nov. 1 target date has raised questions of whether the White House is applying political pressure to speed the vaccine approval process up. President Donald Trump and allies have said a vaccine will be ready by the end of the year or sooner, apparently seeking a political boost with the presidential election two months away. 

On that topic, Slaoui said that for the Warp Speed crew, “there is absolutely nothing to do with politics.” 

“Many of us may or may not be supportive of this administration. It’s irrelevant, frankly,” he noted. In a separate interview, Slaoui told Science he would “immediately resign if there is undue interference in the vaccine process.” 

The former GlaxoSmithKline vaccine exec was named head of Operation Warp Speed back in May. At the time, he said he was “confident” the U.S. would have a vaccine by the end of the year. 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026